Multidrug Therapy Has Redefined Kidney Protection in Diabetic Kidney Disease

Key Takeaways

• Multidrug therapy has transformed diabetic kidney disease (DKD) management beyond glucose and blood pressure control, with randomized controlled trials (RCTs) showing meaningful reductions in kidney disease progression and cardiovascular outcomes using renin-angiotensin-aldosterone system (RAAS) inhibitors, SGLT2 inhibitors, nonsteroidal mineralocorticoid receptor antagonist (MRAs) (finerenone), and GLP-1 receptor agonists.
• Landmark trials (eg, CREDENCE, DAPA-CKD, EMPA-KIDNEY, FIDELIO-DKD, FLOW) demonstrate significant risk reductions in kidney failure, estimated glomerular filtration rate (eGFR) decline, and cardiovascular events across drug classes.
• Emerging evidence supports combination therapy (eg, SGLT2 inhibitors + finerenone) for additive benefits, signaling a shift toward individualized, mechanism-based multidrug regimens as the future standard of care in DKD.

Modern multidrug therapy has transformed DKD from a condition managed mainly with glucose and blood pressure control into one in which kidney and cardiovascular outcomes can be meaningfully improved, according to a study published in Cardiorenal Medicine.

DKD remains the leading cause of chronic kidney disease and kidney failure worldwide, affecting about 30% to 40% of people with diabetes. In a narrative review of pivotal randomized trials from 1990 to 2025, investigators trace the evolution of treatment over 3 decades. “This review summarizes the evidence from pivotal RCTs, highlights clinical implications, and outlines future directions for individualized management of DKD,” wrote the authors.

Trials such as DCCT/EDIC and UKPDS showed that improved control of glucose and blood pressure reduced microvascular complications, including kidney disease. A major shift followed with the introduction of renin–angiotensin system inhibitors. In the captopril trial of 409 patients with type 1 diabetes and nephropathy, captopril reduced the risk of doubling serum creatinine or kidney failure by 48% over 3 years and cut the risk of death, dialysis, or transplantation by 50%. In type 2 diabetes, IRMA-1, IDNT, and RENAAL confirmed that angiotensin receptor blockers, such as irbesartan and losartan, significantly reduced the progression of kidney disease, independent of blood pressure control.

The therapeutic landscape broadened again with sodium-glucose cotransporter-2 (SGLT2) inhibitors. In EMPA-REG OUTCOME, empagliflozin reduced the risk of progression to macroalbuminuria by 38%, the risk of doubling serum creatinine by 44%, and the risk of initiating renal replacement therapy by 55%. CREDENCE showed canagliflozin reduced the composite of kidney failure, doubling of serum creatinine, or renal/cardiovascular death by 30%, while DAPA-CKD found dapagliflozin cut the risk of sustained eGFR decline, kidney failure, or renal/cardiovascular death by 36.9%. In EMPA-KIDNEY, empagliflozin lowered the risk of chronic kidney disease progression or cardiovascular death by 23%.

More recently, finerenone extended protection beyond RAAS blockade. In FIDELIO-DKD, it reduced the risk of kidney failure, sustained eGFR decline, or renal death, with a hazard ratio of 0.82, while FIGARO-DKD showed significant cardiovascular benefit, including a 29% reduction in heart failure hospitalizations. The CONFIDENCE study then suggested additional benefit from combining finerenone with empagliflozin, producing a 29% to 32% greater reduction in albuminuria than either drug alone. Finally, the FLOW trial showed semaglutide reduced major kidney events by 24% (HR 0.76) and cardiovascular death by 29% (HR 0.71).

“Multidrug regimens that combine hemodynamic, metabolic, and anti-inflammatory strategies are likely to define the future standard of care, while precision approaches promise to further refine outcomes in this high-risk population,” concluded the study authors.

Reference

Husain-Syed F, Yuecel G, Daschner C, Jochims J, Yazdani B. Therapeutic advances in diabetic kidney disease: 30 years of evidence and the rise of the "Fantastic Four" in nephrology. Cardiorenal Med. 2026;16(1):44-57. doi:10.1159/000550423